An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.

被引：16
|
作者：
Dummer, R.
Rinderknecht, J.
Goldinger, S. M.
Wagner, I.
Mitchell, L.
Veronese, M. L.
Nick, S.
Hilfiker, P.
Gobbi, S.
机构：
[1] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[2] F Hoffmann La Roche, Basel, Switzerland
[3] F Hoffmann La Roche, Reinach, Switzerland
[4] MRI Bethanien, Zurich, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.8548
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8548
引用
收藏
页数：1
相关论文
共 50 条
  • [31] An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
    Stringer-Reasor, Erica M.
    May, Jori E.
    Olariu, Eva
    Caterinicchia, Valerie
    Li, Yufeng
    Chen, Dongquan
    Della Manna, Deborah L.
    Rocque, Gabrielle B.
    Vaklavas, Christos
    Falkson, Carla I.
    Nabell, Lisle M.
    Acosta, Edward P.
    Forero-Torres, Andres
    Yang, Eddy S.
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [32] An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
    Erica M. Stringer-Reasor
    Jori E. May
    Eva Olariu
    Valerie Caterinicchia
    Yufeng Li
    Dongquan Chen
    Deborah L. Della Manna
    Gabrielle B. Rocque
    Christos Vaklavas
    Carla I. Falkson
    Lisle M. Nabell
    Edward P. Acosta
    Andres Forero-Torres
    Eddy S. Yang
    Breast Cancer Research, 23
  • [33] Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
    Carlos R. Becerra
    Ramon Salazar
    Rocio Garcia-Carbonero
    Anne L. Thomas
    Federico J. Vázquez-Mazón
    James Cassidy
    Tim Maughan
    Manuel Gallén Castillo
    Tim Iveson
    Donghua Yin
    Stephanie Green
    Emily K. Bergsland
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 695 - 702
  • [34] A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAFV600E mutation-positive metastatic melanoma
    J. F. Grippo
    W. Zhang
    D. Heinzmann
    K. H. Yang
    J. Wong
    A. K. Joe
    P. Munster
    N. Sarapa
    A. Daud
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 103 - 111
  • [35] Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
    Becerra, Carlos R.
    Salazar, Ramon
    Garcia-Carbonero, Rocio
    Thomas, Anne L.
    Vazquez-Mazon, Federico J.
    Cassidy, James
    Maughan, Tim
    Gallen Castillo, Manuel
    Iveson, Tim
    Yin, Donghua
    Green, Stephanie
    Bergsland, Emily K.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 695 - 702
  • [36] Clinical experience with the targeted therapy in melanoma patients with brain metastases.
    Zhukova, Natalia, V
    Orlova, Rashida
    Antimonik, Nina
    Beliak, Natalia P.
    Kutukova, Svetlana
    Vasyusina, Olga
    Popova, Natalia, V
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)
    Weber, J.
    Long, G. V.
    Haanen, J. B.
    Arance, A.
    Dummer, R.
    Nathan, P.
    Ribas, A.
    Ascierto, P. A.
    Robert, C.
    Gasal, E.
    D'Amelio, A., Jr.
    Bettinger, S.
    Boran, A. D.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.
    Kluger, Harriet M.
    Goldberg, Sarah B.
    Sznol, Mario
    Tsiouris, John
    Vortmeyer, Alexander
    Jilaveanu, Lucia
    Ralabate, Amanda L.
    Rivera, Angel L.
    Burke, Matthew M.
    Hegbe, Upendra P.
    Cohen, Justine Vanessa
    Yao, Xiaopan
    Speaker, Stephanie
    Madura, Matthew
    Knapp-Perry, Elizabeth
    Mahajan, Amit
    Chiang, Veronica
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer
    de Boer, R.
    Humblet, Y.
    Wolf, J.
    Nogova, L.
    Ruffert, K.
    Milenkova, T.
    Smith, R.
    Godwood, A.
    Vansteenkiste, J.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 486 - 491
  • [40] An open-label study to evaluate the efficacy of retreatment of patients with psoriasis who have previously been treated with etanercept
    Vitiello, Magalys
    Abuchar, Adriana
    Grant, Annika
    Kerdel, Francisco
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB35 - AB35
12345